| Name | Title | Contact Details |
|---|
DNA2.0 is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Menlo Park, CA. To find more information about DNA2.0, please visit www.dnatwopointo.com
Kyros is committed to breaking down barriers, creating a community of support, and making a lasting impact on the lives of those affected by SUD. Through innovative training models, compassionate peer support, and a focus on human-centered solutions, Kyros strives to redefine recovery and provide hope for a healthier future. Founded in 2021 by Daniel Larson, after he encountered obstacles in his own journey with substance use disorder, Kyros` mission is to increase positive outcomes for the millions of Americans managing their own recovery or dedicating their lives to help others find support and wellbeing.
The Roberts Group, Inc. is a Waukesha, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Boston Ivf is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
scPharmaceuticals, based in Lexington, MA, is a privately held biopharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery. Based on widely used generic drugs that currently require intravenous or intramuscular injections, our innovative products will be administered subcutaneously via a proprietary patch pump. This avoids material risks and costs associated with the current delivery options. Our lead products are the first subcutaneous formulations of furosemide (the most widely used parenteral diuretic in treating heart failure) and ceftriaxone (the most widely used parenteral antibiotic outside the hospital setting). Our novel furosemide formulation enables convenient anytime anywhere use, for example in an outpatient setting instead of the emergency room or other in-patient settings. For ceftriaxone and other antibiotics, subcutaneous administration eliminates the need for PICCs (peripherally inserted central catheters), which are associated with serious complications, frequent adverse events and high medical cost. For further information on how we are transforming the administration of parenteral drugs.